Canada · Delayed Price · Currency is CAD Medicure Company Description
Medicure Inc., a biopharmaceutical company, engages in the research, development, and commercialization of human therapies for the cardiovascular market in Canada and the United States.
The company markets and distributes AGGRASTAT injection, a glycoprotein GP IIb/IIIa receptor antagonist for the treatment of acute coronary syndrome, including unstable angina and non-Q-wave myocardial infarction.
It also offers ZYPITAMAG to treat patients with primary hyperlipidemia or mixed dyslipidemia. In addition, the company offers ReDS, a non-invasive medical device that offers measurement of lung fluid for the management of congestive heart failure.
Further, the company offers Sodium Nitroprusside injection for the reduction of blood pressure for adult and pediatric patients in hypertensive crisis, as well as for producing controlled hypotension to reduce bleeding during surgery, and for the treatment of acute congestive heart failure.
It offers products through retail pharmacies, as well as online. The company was incorporated in 1997 and is headquartered in Winnipeg, Canada.
| Country | Canada |
| Founded | 1997 |
| Industry | Drug Manufacturers - Specialty & Generic |
| Sector | Healthcare |
| CEO | Albert Friesen |
Contact Details
Address: 2-1250 Waverley Street Winnipeg, MB MB Canada | |
| Phone | 204 487 7412 |
Stock Details
| Ticker Symbol | MPH |
| Exchange | TSX Venture Exchange |
| Fiscal Year | January - December |
| Reporting Currency | CAD |
| ISIN Number | CA58469E4085 |
| SIC Code | 2836 |
Key Executives
| Name | Position |
|---|---|
| Dr. Albert David Friesen Ph.D. | Founder, Chief Executive Officer, President and Chairman of the Board |
| Dr. Reuben Saba Ph.D. | Vice President of Scientific and Medical Affairs |